Previous Close | 0.1400 |
Open | 0.1400 |
Bid | 0.0000 |
Ask | 5.0000 |
Strike | 90.00 |
Expire Date | 2024-05-17 |
Day's Range | 0.1400 - 0.1400 |
Contract Range | N/A |
Volume | |
Open Interest | 2 |
Additional analyses of data from AURORA, as well as the full adult data set from BEACONUpdated data from the ongoing Phase 1b study of DISC-0974 in myelofibrosis (MF) patients with anemia, including a larger data set and longer follow-up, to be shared in a posterPreliminary data on safety and pharmacodynamic activity from initial single-ascending dose (SAD) cohorts of phase 1 study of DISC-3405 in healthy volunteers WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:I
WATERTOWN, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Monday, May 20th at 10:30 am ET. A live webcast of the fireside chat will be available through the
Aligns Closely With Analyst Projections Amidst Strategic Clinical Advancements